Liver Resection After Selective Internal Radiation Therapy with Yttrium-90: Safety and Outcomes.


Journal

Journal of gastrointestinal cancer
ISSN: 1941-6636
Titre abrégé: J Gastrointest Cancer
Pays: United States
ID NLM: 101479627

Informations de publication

Date de publication:
Mar 2020
Historique:
pubmed: 27 3 2019
medline: 4 11 2020
entrez: 27 3 2019
Statut: ppublish

Résumé

Selective internal radiotherapy (SIRT) with yttrium-90 (Y-90) is an intra-arterial therapy for hepatic malignancy in patients who are unsuitable for surgical resection. This treatment is considered palliative, although some patients can demonstrate a response that is adequate to facilitate surgical resection with curative intent. All patients who underwent liver resection post SIRT were reviewed. Data gathered included patient demographics, tumor type, surgical details, and post-operative outcomes. Twelve patients underwent SIRT followed by liver resection (7 males and 5 females). Pathologies were hepatocellular carcinoma (n = 5), metastatic colorectal cancer (n = 5), and neuroendocrine tumor (n = 2). Lesional response (size, volume, and RECIST (response evaluation criteria in solid tumors)) was calculated and where appropriate functional liver remnant (FLR) is presented. Mean FLR increase was 264cm In selected cases, liver resection is possible post SIRT. As this can represent a potentially curative option, it is important to reconsider resection in the follow-up of patients undergoing SIRT. Post-operative complications are noted following major and extended liver resection. Therefore, further studies are needed to improve patient selection.

Identifiants

pubmed: 30911980
doi: 10.1007/s12029-019-00221-0
pii: 10.1007/s12029-019-00221-0
pmc: PMC7000505
doi:

Substances chimiques

Yttrium Radioisotopes 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

152-158

Références

J Gastrointest Oncol. 2015 Oct;6(5):469-78
pubmed: 26487939
Biosci Trends. 2015 Oct;9(5):289-98
pubmed: 26559021
Lancet. 2008 Mar 22;371(9617):1007-16
pubmed: 18358928
J Gastrointest Oncol. 2014 Jun;5(3):178-89
pubmed: 24982766
Dig Dis Sci. 2006 Aug;51(8):1404-12
pubmed: 16838117
Hepatology. 2014 May;59(5):1864-73
pubmed: 24259442
J Hepatol. 2002 Aug;37(2):240-6
pubmed: 12127429
J Nucl Med. 2014 Sep;55(9):1404-10
pubmed: 25012459
Cardiovasc Intervent Radiol. 2018 May;41(5):816-820
pubmed: 29468286
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
HPB (Oxford). 2015 Oct 16;:
pubmed: 26472490
Liver Cancer. 2015 Mar;4(1):6-15
pubmed: 26020025
Br J Surg. 2003 Jan;90(1):33-41
pubmed: 12520572
Trials. 2014 Dec 03;15:474
pubmed: 25472660
HPB (Oxford). 2014 Mar;16(3):243-9
pubmed: 23530966
Cancer. 2008 Apr 1;112(7):1538-46
pubmed: 18260156
Ann Surg Oncol. 2015 Feb;22(2):467-74
pubmed: 25190114
J Vasc Interv Radiol. 2018 Nov;29(11):1502-1510.e1
pubmed: 30268638
BMC Cancer. 2014 Dec 01;14:897
pubmed: 25487708
World J Surg Oncol. 2014 Jul 01;12:198
pubmed: 24980217
J Surg Oncol. 2015 Sep;112(4):436-42
pubmed: 26256832
Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1552-63
pubmed: 15590187
Future Oncol. 2014 Nov;10(15 Suppl):65-7
pubmed: 25478771
J Clin Pathol. 2013 Mar;66(3):205-11
pubmed: 23162108
Dig Dis Sci. 2008 Sep;53(9):2556-63
pubmed: 18231857
Ann Surg Oncol. 2017 Apr;24(4):906-913
pubmed: 27878478
Case Rep Surg. 2014;2014:712572
pubmed: 24716079
Liver Cancer. 2016 Oct;5(4):303-311
pubmed: 27781202
J Clin Oncol. 2007 Mar 20;25(9):1099-106
pubmed: 17369573
Medicine (Baltimore). 2016 Jun;95(24):e3941
pubmed: 27311006
Cancer Treat Rev. 2016 Nov;50:148-154
pubmed: 27690234
Hepatol Res. 2010 Apr;40(4):311-7
pubmed: 20070396
J Clin Oncol. 2016 May 20;34(15):1723-31
pubmed: 26903575
Lancet Oncol. 2017 Sep;18(9):1159-1171
pubmed: 28781171
Future Oncol. 2014 Nov;10(15 Suppl):49-52
pubmed: 25478767
Future Oncol. 2014 Nov;10(15 Suppl):53-5
pubmed: 25478768
Anticancer Res. 2010 Jul;30(7):3005-7
pubmed: 20683046

Auteurs

Sebastian Mafeld (S)

Department of Interventional Radiology, Freeman Hospital, Freeman Road, High Heaton, Newcastle upon Tyne, NE7 7DN, UK. sebastian.mafeld@gmail.com.

Peter Littler (P)

Department of Interventional Radiology, Freeman Hospital, Freeman Road, High Heaton, Newcastle upon Tyne, NE7 7DN, UK.

Hannah Hayhurst (H)

Department of Hepatobiliary Surgery, Freeman Hospital, Newcastle upon Tyne, NE7 7DN, UK.

Derek Manas (D)

Department of Hepatobiliary Surgery, Freeman Hospital, Newcastle upon Tyne, NE7 7DN, UK.

Ralph Jackson (R)

Department of Interventional Radiology, Freeman Hospital, Freeman Road, High Heaton, Newcastle upon Tyne, NE7 7DN, UK.

John Moir (J)

Department of Hepatobiliary Surgery, Freeman Hospital, Newcastle upon Tyne, NE7 7DN, UK.

Jeremy French (J)

Department of Hepatobiliary Surgery, Freeman Hospital, Newcastle upon Tyne, NE7 7DN, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH